Genmab announces positive interim data fro the Humx-CD20 phase II RA study
The medicon Valley Academy member Genmab announced 5 December positive results from an interim analysis of the first 100 patients in the ongoing Phase II rheumatoid arthritis (RA) study. A statistically significant proportion of patients on active treatment obtained a 20% improvement of the American College of Rheumatology (ACR) response compared to patients treated with placebo. Correspondingly, in all groups treated with HuMax-CD20, a greater proportion of patients benefited from moderate or good EULAR responses compared to placebo.
Rates of overall adverse events were comparable between the 3 groups of patients receiving HuMax-CD20 these were primarily infusion related and do not limit plans for continued development. Serious infections among treated patients were confined to one event of bronchopneumonia in the 300 mg dose group.
With this data in hand, Genmab will start planning Phase III studies. These studies are expected to begin in 2007.
Source: Press-release Genmab 05.12.2006.
Read more at the Genmab homepage.